I don't think these new found issues are going to affect Carfilzomib in the long run. As I mentioned in previous posting, these issues are found in the context of single arm trial, and inadequate mitigation strategy for cardiac and hepatic risks. Velcade has similar and more than these risks, the difference - read Velcade label - is to identify patients at risk with clearly pre-defined dose reduction strategy.
Market Data 
Markets 
AI
